Back to Search Start Over

The combination of olaparib (Poly ADP-ribose polymerase inhibitor) with neratinib (pan-HER inhibitor) is synergistic in uterine serous carcinoma overexpressing HER2.

Authors :
Yadav, G.
Lopez, S.
Han, C.
Altwerger, G.
Menderes, G.
Bellone, S.
Bianchi, A.
Ratner, E.S.
Schwartz, P.E.
Santin, A.D.
Source :
Gynecologic Oncology. Jul2019:Supplement 1, Vol. 154, p34-34. 1p.
Publication Year :
2019

Subjects

Subjects :
*POLY(ADP-ribose) polymerase
*POLY ADP ribose
*CARCINOMA

Details

Language :
English
ISSN :
00908258
Volume :
154
Database :
Academic Search Index
Journal :
Gynecologic Oncology
Publication Type :
Academic Journal
Accession number :
137359985
Full Text :
https://doi.org/10.1016/j.ygyno.2019.04.082
Full Text Access
View/download PDF

Tools

Authors Abstract Subjects Details